Department of General Medicine, Rajendra Institute of Medical Sciences, Ranchi, India.
Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA.
Am J Cardiovasc Drugs. 2020 Dec;20(6):517-524. doi: 10.1007/s40256-020-00402-4.
The health benefit of fish oil, i.e. omega-3 fatty acids (ω-3 FA) has a long history of debate. While there are a number of medications to reduce serum triglyceride levels, none have shown unanimous cardiovascular (CV) benefits. The most recent Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) assessing the CV outcome of one highly purified prescription ω-3 FA has certainly rejuvenated the debate. While this trial has been regarded as one of the most important landmark trials in preventive cardiology, the tolerability issue in a very high dose (4 g/day, as administered in the trial) is still a matter of concern. This article summarizes the current status and future perspective of icosapent ethyl in clinical practice in light of REDUCE-IT.
鱼油（即 ω-3 脂肪酸）对健康的益处一直存在争议。虽然有许多药物可以降低血清甘油三酯水平，但没有一种药物显示出一致的心血管益处。最近的一项评估高纯度处方 ω-3 脂肪酸心血管结局的 REDUCE-IT 试验（REDUCE-IT）肯定重新引发了这场争论。虽然这项试验被认为是预防心脏病学领域最重要的里程碑试验之一，但高剂量（试验中给予的 4 克/天）的耐受性问题仍然令人关注。本文根据 REDUCE-IT 试验，总结了依泽替米贝在临床实践中的现状和未来展望。
